logo-loader
BioPorto

BioPorto reports 20% increase in revenue growth for 1Q

BioPorto A/S (CPH:BIOPOR) CFO Ole Larsen tells Proactive Investors the Denmark-based company grew revenue by 20% to 5.5 million krones compared to 4.6 million krones last year.

Larsen says its continued focus on Research Use Only sales has doubled revenues from The NGAL Test in the US and sales of antibodies are positively affected by higher bulk orders.

Quick facts: BioPorto

Price: £0.00

Market: NASDAQ OMX
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: The Green Organic Dutchman delivers first order to Ontario...

The Green Organic Dutchman (TSE:TGOD-US: TGODF) Director of National Sales, Ed Corcoran joined Steve Darling from Proactive Vancouver to discuss the company delivering their first order to the Ontario Cannabis Store. Corcoran telling Proactive when their product will be available in retail...

1 day, 15 hours ago

2 min read